Evidence based review of management of cardiorenal syndrome type 1

Table 4 Changes in clinical parameters of the included studies

Intervention	Clinical parameters evaluated
	Ref.	Creatinine (mg/dL)		Change in BUN (mg/dL)		Cystatin C (mg/L)		GFR (mL/min)		Urine output (mL/d)
		Baseline	72 h	Baseline	72 h	Baseline	72 h	Baseline	72 h	Baseline	72 h
Levosimendan	Fedele et al[12], 2014	1.76 ± 0.37	1.51 ± 0.5	45.08 ± 22.19	33.14 ± 16.63	2577.5 ± 700.6	2083 ± 731.4	38.71 ± 7.94	53.34 ± 14.93	1766.4 ± 514.2	2663.5 ± 721.2
	Fedele et al[12], 2014 (placebo)	1.6 ± 0.2	1.7 ± 0.2	44.4 ± 13.1	47 ± 12.8	2498.5 ± 262	2470 ± 409.9	43.33 ± 7.99	40.24 ± 6.58	1571.4 ± 125.3	1778.51 ± 798.1
	Ref.	Creatinine (mg/dL)		Change in BUN (mg/dL)		RBF (mL/min)		GFR (mL/min)		FF
		Baseline	Treatment	Baseline	Treatment	Baseline	Treatment	Baseline	Treatment	Baseline	Treatment
	Inomata et al[14], 2017	NA	NA	NA	NA	426 ± 197	518 ± 276	36.5 ± 18.3	44.5 ± 19.0	0.146 ± 0.080	0.143 ± 0.069

BUN: Blood urea nitrogen; FF: filtration fraction; GFR: glomerular filtration rate; NA: Not available; RBF: renal blood flow.